{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:01:06Z","timestamp":1789909266834,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2172,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1093\/annonc\/mdt396","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T16:19:50Z","timestamp":1381508390000},"page":"3045-3050","source":"Crossref","is-referenced-by-count":48,"title":["DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma"],"prefix":"10.1016","volume":"24","author":[{"given":"S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Benzidane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cazorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Demarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kaliski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Delabrousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Letondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Bosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Valmary-Degano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt396_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973\u20132000","volume":"1012","author":"Johnson","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt396_bb0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.6004\/jnccn.2012.0046","article-title":"Anal carcinoma, version 2.2012: featured updates to the NCCN guidelines","volume":"104","author":"Benson","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mdt396_bb0020","first-page":"300","article-title":"Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal","volume":"153","author":"Wilking","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdt396_bb0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10637-006-7667-x","article-title":"Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282","volume":"245","author":"Jhawer","year":"2006","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdt396_bb0030","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/1097-0142(20010801)92:3<642::AID-CNCR1365>3.0.CO;2-Z","article-title":"Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a phase II trial","volume":"923","author":"Hainsworth","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt396_bb0035","first-page":"861","article-title":"5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer","volume":"8610","author":"Faivre","year":"1999","journal-title":"Bull Cancer"},{"issue":"Suppl. 5","key":"10.1093\/annonc\/mdt396_bb0040","doi-asserted-by":"crossref","first-page":"v87","DOI":"10.1093\/annonc\/mdq171","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Glynne-Jones","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt396_bb0045","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"3016","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt396_bb0050","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98\u201311 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"3035","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt396_bb0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0196-72","article-title":"Loss of normal p53 function confers sensitization to taxol by increasing G2\/M arrest and apoptosis","volume":"21","author":"Wahl","year":"1996","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdt396_bb0060","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"636","author":"Scheffner","year":"1990","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdt396_bb0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(10)70279-5","article-title":"Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial","volume":"122","author":"Lorch","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt396_bb0070","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.humpath.2012.08.019","article-title":"Signature patterns of human papillomavirus type 16 in invasive anal carcinoma","volume":"44","author":"Valmary-Degano","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdt396_bb0075","first-page":"4637","article-title":"Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy","volume":"3112","author":"Abbas","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdt396_bb0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00384-008-0467-3","article-title":"Activity of paclitaxel in metastatic squamous anal carcinoma","volume":"237","author":"Alcindor","year":"2008","journal-title":"Int J Colorectal Dis"},{"key":"10.1093\/annonc\/mdt396_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000259615","article-title":"Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status","volume":"77","author":"Lukan","year":"2009","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdt396_bb0090","first-page":"163736","article-title":"A regimen of taxol, ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal","volume":"2011","author":"Golub","year":"2011","journal-title":"Chemother Res Pract"},{"key":"10.1093\/annonc\/mdt396_bb0095","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.2008.20.2853","article-title":"Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck","volume":"2712","author":"Lassen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt396_bb0100","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","article-title":"Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial","volume":"2827","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt396_bb0105","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2007.12.7662","article-title":"EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer","volume":"2619","author":"Kumar","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/12\/3045\/16702179\/mdt396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:31:21Z","timestamp":1624519881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419367389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0923753419367389"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt396","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}